<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114496">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612650</url>
  </required_header>
  <id_info>
    <org_study_id>TOMOSEIN-1104</org_study_id>
    <secondary_id>2011-002051-34</secondary_id>
    <nct_id>NCT01612650</nct_id>
  </id_info>
  <brief_title>Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis</brief_title>
  <acronym>TOMOSEIN</acronym>
  <official_title>Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess if using tomosynthesis for breast cancer surveillance will allow a
      significant decrease of ultrasound cliches (and radiation exposure)
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the benefit of tomosynthesis for diagnosis</measure>
    <time_frame>30 months</time_frame>
    <description>number of avoided focused cliches and ultrasound, after tomosynthesis analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine best incidence of realization</measure>
    <time_frame>30 months</time_frame>
    <description>face, medial side or oblique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of breast irradiation</measure>
    <time_frame>30 months</time_frame>
    <description>comparison of tomosynthesis irradiation and focused cliches irradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate non focused ultrasound residual place for 2 - 3 - 4 density breast</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of additional cancer detected by tomosynthesis</measure>
    <time_frame>30 months</time_frame>
    <description>number of breast cancer detected through tomosynthesis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1172</enrollment>
  <condition>Breast Cancer</condition>
  <condition>2D Mammography</condition>
  <condition>3D Mammography</condition>
  <arm_group>
    <arm_group_label>breast cancer histologically proven</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient with breast cancer histologically proven, addressed to Oscar Lambret Center for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>surveillance of a treated breast cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>surveillance of patient already treated for breast cancer must have annual mammography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diagnosis of a detected anomaly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient addressed for diagnosis of a detected anomaly</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tomosynthesis</intervention_name>
    <description>2 incidences 3D numeric mammography</description>
    <arm_group_label>breast cancer histologically proven</arm_group_label>
    <arm_group_label>surveillance of a treated breast cancer</arm_group_label>
    <arm_group_label>diagnosis of a detected anomaly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2D mammography</intervention_name>
    <description>2 incidences 2D analogic mammography</description>
    <arm_group_label>breast cancer histologically proven</arm_group_label>
    <arm_group_label>surveillance of a treated breast cancer</arm_group_label>
    <arm_group_label>diagnosis of a detected anomaly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  woman with breast cancer histologically proven (group 1), on surveillance of a
             treated breast cancer (group 2) or diagnosis of an detected anomaly

          -  age ≥ 40 years (group 1, group 2); age ≥ 50 years (group 3)

          -  breast size suitable for detector size

          -  possible prior mastectomy

          -  security social covered

          -  signed informed consent

        Exclusion Criteria:

          -  breast implant

          -  high genetic risk (mutation)

          -  under justice measures

          -  breast feeding or pregnant woman
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie TAIEB, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oscar Lambret Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvette VENDEL</last_name>
    <phone>+33 (0)3.20.29.59.40</phone>
    <email>y-vendel@o-lambret.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oscar Lambret Center</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie TAIEB, MD</last_name>
      <phone>+33 (0)3.20.29.59.18</phone>
      <email>s-taieb@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie TAIEB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc CEUGNART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline CHAVERON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence BACHELLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corinne JUMELLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie ROCOURT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwenaelle POULIQUEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthieu FAIVRE-PIERRET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé BERCEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armelle RENAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas BOULANGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline BECK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier - Pavillon Paul Gelé</name>
      <address>
        <city>Roubaix</city>
        <zip>59100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Aurélie DELESALLE, MD</last_name>
      <phone>33 3 20 99 32 48</phone>
      <email>delesalle.marie@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marie-Aurélie DELESALLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine FREMAUX-ISRAEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perrine FOUVEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trung LE THANH, MD</last_name>
      <phone>33</phone>
    </contact>
    <investigator>
      <last_name>Trung LE THANH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwendoline LEVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas LAURENT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edouard PONCELET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodora SERB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aniela RUSU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des Dentellières</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra SEVERIN, MD</last_name>
      <phone>33 327147500</phone>
      <email>sandra.severin-fontana@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Sandra SEVERIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie GAVAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle DAMAREY-FELDMANN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parta ETASSAMI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain DEDEIRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 20, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>surveillance</keyword>
  <keyword>diagnosis</keyword>
  <keyword>2D mammography</keyword>
  <keyword>3D mammography</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
